Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.22 USD | -10.84% | -2.20% | +26.14% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.14% | 21.26M | - | - | |
+9.21% | 45.97B | B | ||
+52.73% | 43.93B | A | ||
+7.24% | 42.34B | B- | ||
-8.78% | 28.27B | C | ||
+18.20% | 27.18B | B- | ||
-21.28% | 19.44B | B | ||
+14.37% | 13.83B | C+ | ||
+32.31% | 12.4B | C+ | ||
+5.53% | 11.45B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Indaptus Therapeutics, Inc. - Nasdaq
- Ratings Indaptus Therapeutics, Inc.